|
1
|
Fais S: Proton pump inhibitor-induced
tumour cell death by inhibition of a detoxification mechanism. J
Intern Med. 267:515–525. 2010.
|
|
2
|
Rabon EC and Reuben MA: The mechanism and
structure of the gastric H,K-ATPase. Annu Rev Physiol. 52:321–344.
1990.
|
|
3
|
Sachs G, Shin JM and Howden CW: Review
article: the clinical pharmacology of proton pump inhibitors.
Aliment Pharmacol Ther. 23(Suppl 2): 2–8. 2006.
|
|
4
|
Shin JM, Cho YM and Sachs G: Chemistry of
covalent inhibition of the gastric (H+,
K+)-ATPase by proton pump inhibitors. J Am Chem Soc.
126:7800–7811. 2004.
|
|
5
|
Roche VF: The chemically elegant proton
pump inhibitors. Am J Pharm Educ. 70:1012006.
|
|
6
|
Pantoflickova D, Dorta G, Ravic M, Jornod
P and Blum AL: Acid inhibition on the first day of dosing:
comparison of four proton pump inhibitors. Aliment Pharmacol Ther.
17:1507–1514. 2003.
|
|
7
|
Besancon M, Simon A, Sachs G and Shin JM:
Sites of reaction of the gastric H,K-ATPase with extracytoplasmic
thiol reagents. J Biol Chem. 272:22438–22446. 1997.
|
|
8
|
Stubbs M, McSheehy PM and Griffiths JR:
Causes and consequences of acidic pH in tumors: a magnetic
resonance study. Adv Enzyme Regul. 39:13–30. 1999.
|
|
9
|
Stubbs M, Rodrigues L, Howe FA, et al:
Metabolic consequences of a reversed pH gradient in rat tumors.
Cancer Res. 54:4011–4016. 1994.
|
|
10
|
Holm E, Hagmüller E, Staedt U, et al:
Substrate balances across colonic carcinomas in humans. Cancer Res.
55:1373–1378. 1995.
|
|
11
|
Vaupel P, Kallinowski F and Okunieff P:
Blood flow, oxygen and nutrient supply, and metabolic
microenvironment of human tumors: a review. Cancer Res.
49:6449–6465. 1989.
|
|
12
|
Tannock IF and Rotin D: Acid pH in tumors
and its potential for therapeutic exploitation. Cancer Res.
49:4373–4384. 1989.
|
|
13
|
Helmlinger G, Yuan F, Dellian M and Jain
RK: Interstitial pH and pO2 gradients in solid tumors in
vivo: high-resolution measurements reveal a lack of correlation.
Nat Med. 3:177–182. 1997.
|
|
14
|
Yeo M, Kim DK, Kim YB, et al: Selective
induction of apoptosis with proton pump inhibitor in gastric cancer
cells. Clin Cancer Res. 10:8687–8696. 2004.
|
|
15
|
Ke Y, Ning T and Wang B: Establishment and
characterization of a SV40 transformed human fetal gastric
epithelial cell line-GES-1. Zhonghua Zhong Liu Za Zhi. 16:7–10.
1994.(In Chinese).
|
|
16
|
Pérez-Sayáns M, García-García A,
Reboiras-López MD and Gándara-Vila P: Role of V-ATPases in solid
tumors: importance of the subunit C (Review). Int J Oncol.
34:1513–1520. 2009.
|
|
17
|
Pérez-Sayáns M, Somoza-Martín JM,
Barros-Angueira F, Rey JM and García-García A: V-ATPase inhibitors
and implication in cancer treatment. Cancer Treat Rev. 35:707–713.
2009.
|
|
18
|
Trédan O, Galmarini CM, Patel K and
Tannock IF: Drug resistance and the solid tumor microenvironment. J
Natl Cancer Inst. 99:1441–1454. 2007.
|
|
19
|
De Milito A and Fais S: Tumor acidity,
chemoresistance and proton pump inhibitors. Future Oncol.
1:779–786. 2005.
|
|
20
|
Mullin JM, Gabello M, Murray LJ, et al:
Proton pump inhibitors: actions and reactions. Drug Discov Today.
14:647–660. 2009.
|
|
21
|
Fais S, De Milito A, You H and Qin W:
Targeting vacuolar H+-ATPases as a new strategy against
cancer. Cancer Res. 67:10627–10630. 2007.
|
|
22
|
Kromer W, Krüger U, Huber R, Hartmann M
and Steinijans VW: Differences in pH-dependent activation rates of
substituted benzimidazoles and biological in vitro correlates.
Pharmacology. 56:57–70. 1998.
|
|
23
|
Kirchheiner J, Glatt S, Fuhr U, et al:
Relative potency of proton-pump inhibitors - comparison of effects
on intragastric pH. Eur J Clin Pharmacol. 65:19–31. 2009.
|
|
24
|
Marelli S and Pace F: Rabeprazole for the
treatment of acid-related disorders. Expert Rev Gastroenterol
Hepatol. 6:423–435. 2012.
|
|
25
|
De Milito A, Marino ML and Fais S: A
rationale for the use of proton pump inhibitors as antineoplastic
agents. Curr Pharm Des. 18:1395–1406. 2012.
|
|
26
|
Nishi T and Forgac M: The vacuolar
(H+)-ATPases - nature’s most versatile proton pumps. Nat Rev Mol
Cell Biol. 3:94–103. 2002.
|
|
27
|
Hinton A, Bond S and Forgac M: V-ATPase
functions in normal and disease processes. Pflugers Arch.
457:589–598. 2009.
|
|
28
|
Sennoune SR, Luo D and Martínez-Zaguilán
R: Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell
Biochem Biophys. 40:185–206. 2004.
|
|
29
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010.
|
|
30
|
Ballif BA and Blenis J: Molecular
mechanisms mediating mammalian mitogen-activated protein kinase
(MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ.
12:397–408. 2001.
|
